Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
Updated DOC1021 data in newly diagnosed glioblastoma show 90% 12-month overall survival in a predominantly MGMT-unmethylated population, accompanied by immune analyses suggesting immune memory. DOC1021 is now also enrolling in a refractory melanoma clinical study, targeting a population...
Updated DOC1021 data in newly diagnosed glioblastoma show 90% 12-month overall survival in a predominantly MGMT-unmethylated population, accompanied by immune analyses suggesting immune memory. DOC1021 is now also enrolling in a refractory melanoma clinical study, targeting a population...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.